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Abstract Human placental protein 14 (PP14), a member of the
lipocalin structural superfamily, is an abundant amniotic fluid
glycoprotein with documented immunoinhibitory activities. While
receptors have been characterized for several other lipocalins,
none have been reported to date for PP14. In the present study,
two-color immunofluorescence and flow cytometry was used to
screen peripheral blood mononuclear cell subpopulations for their
capacity to engage fluoresceinated recombinant PP14. The
tagged PP14 bound strongly in a specific and saturable fashion
to CD14+ (monocyte lineage) cells, but not to CD20+ (B cell
lineage) or CD3+ (T cell lineage) cells. This binding was both
pH- and temperature-sensitive, and was reduced by proteolytic
pre-digestion of the cells with trypsin or proteinase K. Scatchard
analysis demonstrated a single class of receptors on CD14+ cells,
with a KD of V1U1038 and V10^35 000 receptors per cell.
These findings constitute the first report of a cell surface-
associated binding protein for PP14 and set the stage for
exploring the molecular mechanisms of PP14-mediated signaling
and immunomodulation.
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1. Introduction
Human placental protein 14 (PP14) is an abundant amni-
otic £uid protein produced by epithelial cells within the female
and male reproductive tracts [1,2]. More recently, PP14 has
been identi¢ed in hematopoietic cells, including normal mega-
karyocytes and platelets [3]. This 28-kDa glycoprotein, desig-
nated by assorted names in the literature (including progester-
one-associated endometrial protein [4] and glycodelin [5]) is of
considerable interest due to its remarkable immunomodula-
tory activities, with reported in vitro e¡ects on in£ammatory
cytokine (IL-1 and IL-2) production [6,7] and T cell prolifer-
ation [3,8]. These immunoregulatory activities are evident at
protein concentrations similar to those found in the serum of
pregnant women [2]. This latter observation is especially sig-
ni¢cant, since it raises the intriguing possibility that PP14 may
account, at least in part, for certain immunological phenom-
ena associated with pregnancy (e.g. amelioration of autoim-
mune disease manifestations and skewing of cytokine pro¢les
[9,10]).
Conserved sequence motifs and higher order structural fea-
tures place PP14 into a family of proteins known as ‘lipoca-
lins.’ The three-dimensional structure of lipocalins is typically
characterized by an eight-stranded anti-parallel L-barrel (re-
miniscent of the calyx of a £ower) that forms an internal
pocket for binding small hydrophobic ligands [11]. Retinoids
constitute potential ligands for several of the lipocalins, in-
cluding retinol binding protein (RBP), L-lactoglobulin, K1-mi-
croglobulin, and purpurin [11], as well as for PP14 (Mao, J.
and Tykocinski, M., in preparation).
In addition to binding small hydrophobic ligands internally,
lipocalins are also known to engage speci¢c cell surface recep-
tors. The receptor for RBP is best characterized. Bavik et al.
cloned the cDNA of a 63-kDa RBP-binding membrane pro-
tein on bovine retinal pigment epithelial cells. [12^14]. Siva-
prasadarao et al. showed speci¢c binding of both native and
recombinant RBP to human placental membrane vesicles [15]
and have isolated 63- and 55-kDa receptor proteins using
a⁄nity chromatography [16]. This same group also identi¢ed
a speci¢c receptor for another lipocalin, odorant binding pro-
tein, on bovine nasal mucosa [17]. Receptors for K1-micro-
globulin have been identi¢ed on both PMA-induced U937
cells [18] and mouse splenocytes [19]. Data also support the
existence of a receptor for L-lactoglobulin (the closest lipoca-
lin homologue to PP14) on calf intestine microvilli [20], as
well as a receptor for purpurin [21].
Recently, we succeeded in producing human PP14 for the
¢rst time as a recombinant protein using a prokaryotic ex-
pression system (Mao, J. and Tykocinski, M., in preparation).
Armed with this recombinant protein, we initiated an open-
ended search for a receptor for PP14 on di¡erent hemato-
poietic cell types. We now report the identi¢cation of a cell
surface binding protein for PP14 that is selectively expressed
on the surface of CD14 cells of the monocytic lineage.
2. Materials and methods
2.1. Isolation of cells
Peripheral blood mononuclear cells (PBMC) were isolated from the
blood of healthy volunteer donors by Ficoll-paque (Pharmacia Bio-
tech, Piscataway, NJ, USA) density gradient centrifugation, as previ-
ously described [3]. Enrichment of a non-adherent monocyte popula-
tion for use in 125I-binding assays was accomplished by applying the
total PBMC pool obtained in the initial Ficoll separation to a Percoll
density gradient (Pharmacia) [22]. Cells were washed extensively prior
to use. The resulting population consisted of 20^60% CD14 cells, as
demonstrated by indirect immuno£uorescence.
For experiments requiring enriched lymphoid subsets, PBMC were
depleted of monocytes by adherence to plastic for 1 h at 37‡C in
RPMI-1640 (Gibco-BRL, Grand Island, NY, USA). The non-adher-
ent cells were subsequently treated with LymphoKwik B (One Lamb-
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da, Canoga Park, CA, USA) for B cell enrichment or LymphoKwik T
(One Lambda) for T cell enrichment, using protocols described by the
manufacturer.
2.2. Generation of recombinant PP14
Recombinant human PP14 was generated using a prokaryotic ex-
pression system, to be described in detail elsewhere (Mao, J. and
Tykocinski, M., in preparation). Brie£y, BL2(DE3) E. coli were trans-
formed with the expression construct pPP14.1WEEWhis6/ET-22b(+) (en-
coding full-length human PP14 cDNA with EE [23] and hexahistidine
tags linked in tandem at the carboxyl terminus, and built upon the
periplasmic expression vector pET-22b(+) (Novagen, Madison, WI,
USA)). Fifty ml of an overnight culture grown in terri¢c broth (TB)
[24] containing 100 Wg/ml carbenicillin was used to inoculate 5 l of TB/
carbenicillin. Cultures were incubated in a Bio£ow 3000 biofermenter
(New Brunswick Scienti¢c, Edison, NJ, USA) at 37‡C with stirring at
800 rpm and aeration until an A600 of 6^8 was reached. IPTG (5 g;
Ambion, Austin, TX, USA) was then added to induce expression of
recombinant PP14 protein. The cultures were grown at 37‡C for an
additional 3 h and then harvested by centrifugation. Cell pellets were
resuspended in 2 l of 30 mM Tris-HCl (pH 8.0) and 20% sucrose and
recovered by centrifugation. Pellets were subjected to osmotic shock
by resuspending in 2 l of ice cold 5 mM MgSO4, followed by 10 min
of vigorous shaking. The mixture was centrifuged at 6000Ug for 20
min at 4‡C, and the recombinant hexahistidine-tagged PP14 was pu-
ri¢ed from the resulting supernatant in a single step by Ni2-Sephar-
ose chromatography as described previously [25]. The protein was
concentrated using a Centriprep 10 (Amicon, Beverly, MA, USA),
and the purity of the protein was assessed by 12.5% reducing SDS-
PAGE followed by Coomassie blue staining.
2.3. Proteins and antibodies
Other lipocalins used in binding assays included bovine milk
L-lactoglobulin (Sigma, St. Louis, MO, USA), RBP puri¢ed from
human urine (Sigma), K1-microglobulin puri¢ed from human urine
(Calbiochem, San Diego, CA, USA) and recombinant murine neutro-
phil gelatinase-associated lipocalin (NGAL; 24p3) [26]. Recombinant
hexahistidine-tagged murine 24p3 was produced as a periplasmic pro-
tein by methods similar to those described above for PP14 (Weber, M.
and Tykocinski, M., unpublished data). Proteins used as negative
controls in competition assays included horse heart cytochrome
c (Sigma) and bovine erythrocyte carbonic anhydrase (Sigma).
In addition, recombinant soluble HLA-A2 K3 domain, a hexa-
histidine-tagged, periplasmic protein [25] produced by methods sim-
ilar to those used for recombinant PP14, was used as a negative
control.
The mAbs used in binding assays included anti-leu-16 (an anti-
CD20 mAb), anti-leu-M3 (an anti-CD14 mAb), mouse IgG1 and
IgG2a (Becton-Dickinson). The hybridomas OKT3 (anti-CD3) and
HP6001 (IgG2b isotype control) were obtained from the American
Type Culture Collection (Rockville, MD, USA) and were used to
raise ascites in pristane-primed mice. mAbs were puri¢ed from
mouse ascites by a⁄nity chromatography, as previously described
[25].
2.4. Protein labeling
Recombinant PP14 (0.5^1 mg/ml) was incubated with 10 Wg/ml
£uorescein isothiocyanate (FITC) (Pierce Chemical, Rockford, IL,
USA) in 100 mM carbonate, pH 9.0 for 1 h at RT. Unconjugated
£uorescein was removed by bu¡er exchange into phosphate bu¡ered
saline using a Centricon 10 concentrator (Amicon). L-Lactoglobulin,
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Fig. 1. A: SDS-PAGE analysis of puri¢ed recombinant PP14. A⁄nity-puri¢ed recombinant PP14 (see Section 2) was subjected to 12.5% SDS-
PAGE under reducing conditions, followed by Coomassie Blue staining. Arrows corresponding to the 21.5- and 30-kDa size markers are shown
at the left. B: *F-PP14 binds to the CD14 subpopulation of human PBMC. 106 PBMC were immunostained with mAb directed against sur-
face markers for monocytes (anti-CD14, panels C and D), T cells (anti-CD3, panels E and F) or B cells (anti-CD20, panels G and H) plus a
phycoerythrin-conjugated goat anti-mouse F(abP)2, in the presence (panels B, D, F, H) or absence (A, C, E, G) of 1.5 Wg/ml *F-PP14. Results
are displayed as two-color £ow cytometric contour plots with speci¢c mAb staining on the y-axes and *F-PP14 binding on the x-axes. Only
cells expressing CD14 bound *F-PP14 (panel D), whereas neither T (panel F) nor B (panel H) cells bound *F-PP14. Shown for comparison are
unstained PBMC (panel A; secondary Ab only) and PBMC stained with *F-PP14 alone (panel B; along with secondary Ab). Additional iso-
type-matched control mAbs did not bind to PBMC (not shown). Shown are representative results from one of eight similar experiments.
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horseheart cytochrome c, RBP, and recombinant murine 24p3 were
£uoresceinated in a similar fashion.
Recombinant PP14 was 125I labeled by the peroxidase method [27]
using Na-125I (NEN, Boston, MA, USA) and lactoperoxidase (Cal-
biochem). 125I-labeled PP14 was separated from free 125I by Sephadex
G-25 (Pharmacia) gel ¢ltration. Speci¢c activities of 1.2^5.0U106
cpm/pmol were achieved. RBP and recombinant 24p3 were radio-io-
dinated in a similar fashion.
2.5. Binding assays
For £uorescent cytometric assays, 106 PBMC were incubated with
£uoresceinated recombinant PP14 (*F-PP14) (¢nal concentrations
ranging from 50 to 150 nM) in RPMI-1640 supplemented with
0.75% bovine serum albumin and 0.05% sodium azide for 3 h at
room temperature (RT). During the last 30 min of this incubation
period, a 1:10 dilution of blocking pre-immune rabbit serum (Sigma)
was added. The cells were then immunostained with one of several
mAbs identifying speci¢c mononuclear cell subpopulations for one
hour on ice. Cells were washed with wash bu¡er (PBS with 0.5%
BSA and 0.05% sodium azide), stained with phycoerythrin-conjugated
goat anti-mouse secondary F(abP)2 (Boehringer-Mannheim, Indiana-
polis, IN, USA) for one hour on ice, and analyzed on a FACScan
£ow cytometer (Becton-Dickinson, San Jose, CA, USA). Speci¢city of
binding was determined by competition assays in which 100- to 150-
fold molar excess of recombinant PP14 or irrelevant control protein
was added to the cells just prior to addition of the £uoresceinated
ligand.
In some experiments, PBMC were pre-treated with either a solution
containing trypsin 0.5 g/l and EDTA 0.2 g/l (Gibco-BRL), proteinase
K 0.2 mg/ml (Bethesda Research Laboratories, Gaithersburg, MD,
USA), 10 mM EDTA, or 2 mM dithiothreitol for 30 min at 37‡C.
After three washes, cells were stained with *F-PP14 as described
above. In other experiments, PBMC were treated with 2 mu/ml endo-
glycosidase H (Genzyme Diagnostics, Cambridge, MA, USA) for 3 h
at 37‡C, followed by washing and staining with *F-PP14.
125I-PP14 binding assays were performed as follows: 1.5 ml poly-
propylene microcentrifuge tubes (Laboratory Products Sales, Roches-
ter, NY, USA) were pre-blocked with 2% BSA in PBS for 3 h at RT.
2U106 PBMC enriched for monocytes by Percoll density gradient
centrifugation were incubated with 125I-labeled PP14 in a total volume
of 500 Wl of binding medium (RPMI-1640 with 0.2% BSA and 0.1%
NaN3) for 3 h at RT in the presence of increasing concentrations of
unlabeled recombinant PP14. Unlabeled PP14 was pre-incubated with
the cells for 1 h at RT prior to the addition of labeled PP14. Cells
were then pelleted by centrifugation to separate bound from unbound
radioactive ligand. Pellets were washed twice with binding media, and
bound radioligand was measured using a Q-counter (Beckman, Irvine,
CA, USA). 125I-24p3 and 125I-RBP as ligand were used as negative
controls. Competition studies were similarly performed using unla-
beled K1-microglobulin. Data was analyzed and Scatchard plots gen-
erated using the KELL for Windows program (Biosoft, Ferguson,
MO, USA).
3. Results
Recombinant human PP14 was isolated from the periplasm
of BL21(DE3) E. coli transformed with the bacterial expres-
sion vector pPP14.1WEEWhis6/ET-22b(+). The hexahistidine-
tagged PP14 protein was a⁄nity-puri¢ed from periplasmic
extracts of these bacteria by metal chelate chromatography,
and its relative purity was veri¢ed by Coomassie blue-stained
SDS-PAGE (Fig. 1A). The non-glycosylated bacterial protein
product migrated as a homogeneous band slightly faster than
the estimated V28-kDa size of native N-glycosylated human
PP14 [28].
Two-color immuno£uorescence and £ow cytometric analy-
sis was used to screen di¡erent mononuclear cell subpopula-
tions for their capacity to bind to £uorescein-conjugated PP14
(*F-PP14). The £uoresceinated PP14 ligand was used either
alone or in combination with one of several mAbs directed
against cell type-speci¢c surface epitopes (CD3 as a pan-T cell
marker, CD20 as a pan-B cell marker, and CD14 as a mono-
cyte marker) or equal concentrations of isotype-matched con-
trol Abs. A representative experiment is shown in Fig. 1B.
When used alone, *F-PP14 bound to a proportion of un-
fractionated PBMC (Fig. 1B, panels A and B). In di¡erent
donor samples, the percentage of ligand-binding cells ranged
from 13 to 28%. Interestingly, *F-PP14 was found to selec-
tively associate with the CD14 subset, corresponding to the
monocytic cell fraction (Fig. 1B, panels C and D). The entire
CD14 population shifted to the right in these £ow cytometric
contour plots, indicating homogeneous binding of the labeled
ligand (Fig. 1B, panel D). In contrast, there was no signi¢cant
binding of *F-PP14 to either CD3 T cells (Fig. 1B, panels E
and F) or CD20 B cells (Fig. 1B, panels G and H).
Puri¢ed lymphocyte subpopulations were also investigated
for binding to *F-PP14. Enriched T and B lymphocyte sub-
populations depleted of monocytes by adherence and lysis by
antibody and complement failed to bind *F-PP14 (data not
shown). Isotype-matched control mAbs corresponding to the
isotypes of the CD14, CD3 and CD20 mAbs did not bind to
any of the cells.
The binding of *F-PP14 to CD14 monocytes was both
speci¢c and saturable. Binding was substantially reversed by
adding a 150-fold excess of unlabeled recombinant PP14 (Fig.
2B). In contrast, similar concentrations of an irrelevant hex-
ahistidine-tagged periplasmic protein (HLA-A2.1K3) failed to
reverse the binding of *F-PP14 to monocytes (Fig. 2C).
CD14 monocytes also failed to bind *F-cytochrome c (not
shown).
To test degeneracy of binding to the putative monocyte
receptor among lipocalin family members, puri¢ed L-lactoglo-
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Fig. 2. Binding of *F-PP14 to CD14 monocytes is speci¢c and sat-
urable. 106 anti-CD14-stained PBMC were incubated with *F-PP14
(3 Wg/ml) in the absence (panel A) or presence (panel B) of a 150-
fold excess of unlabeled recombinant PP14. Unlabeled PP14 signi¢-
cantly inhibited binding of *F-PP14 to CD14 cells (panel B). Simi-
lar concentrations of an unlabeled control protein (HLA-A2.1K3),
failed to reverse binding of *F-PP14 to CD14 cells (panel C).
Numbers shown correspond to percentage of cells analyzed that lie
within the indicated sector.
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bulin, RBP, and murine 24p3 were each £uorescein-labeled
and used as ligand probes. Fluoresceinated L-lactoglobulin
bound to CD14 cells (Fig. 3C), though to a lesser degree
than did *F-PP14 (Fig. 3A). The binding between *F-L-lacto-
globulin and the CD14 monocytes was inhibited by a 100-
fold excess of unlabeled recombinant PP14 (Fig. 3D). Con-
versely, the binding of *F-PP14 was also partially inhibited by
an excess of unlabeled L-lactoglobulin (not shown). In con-
trast, neither *F-RBP (Fig. 3E) nor *F-24p3 (Fig. 3F) bound
to the CD14 cells. Thus, lipocalins do not promiscuously
bind to CD14 monocytes, although at least two lipocalins,
PP14 and L-lactoglobulin, do so. Moreover, the cross-block-
ing ¢ndings suggest that the two bind to the same surface
receptor. Similar cross-blocking has been observed for two
other lipocalins (odorant-binding protein and major urinary
protein) in binding to the receptor for odorant-binding pro-
tein [17].
The receptor on CD14 monocytes for *F-PP14 was fur-
ther characterized. *F-PP14 binding to the cells was signi¢-
cantly reduced by protease digestion of PBMC with either
trypsin (Fig. 4A) or proteinase K (Fig. 4B), substantiating
that the receptor is a protein. While sensitive to proteolysis,
the receptor’s capacity to engage PP14 was not reduced by
endoglycosidase H treatment of the PBMC. Preincubation of
PBMC with EDTA or the reducing agent dithiothreitol failed
to reduce the binding of *F-PP14 to monocytes (data not
shown), suggesting that neither divalent cations nor disul¢de
bonds are essential for binding.
The temperature and pH sensitivity of *F-PP14 binding to
monocytes were next evaluated. Signi¢cant binding was ob-
served at both 37‡C and 20‡C, with less detectable binding at
0‡C (Fig. 5A). Binding was also found to be pH-dependent
(Fig. 5B). Maximal binding occurred at neutral pH (7.5), with
decreased binding at lower and higher pHs. Taken together,
the protease, temperature, and pH sensitivities are consistent
with a polypeptide receptor for PP14.
In order to substantiate the ¢ndings with *F-PP14, 125I-
PP14 was used as ligand in radiometric assays. 125I-PP14
bound to PBMC enriched for non-adherent monocytes, and
cold competition with unlabeled PP14 demonstrated saturable
FEBS 20944 8-10-98
Fig. 4. Protease sensitivity of the PP14 receptor. 106 PBMC were
pre-treated with either trypsin (panel A) or proteinase K (panel B),
and subsequently stained with *F-PP14 (4.0 Wg/ml). FACS histo-
grams of monocyte-gated PBMC depicting *F-PP14 binding are
shown. Legend: 999, unstained cells; - - -, protease-treated/*F-
PP14-stained cells; W W W, untreated/*F-PP14-stained cells.
Fig. 5. Temperature dependency and pH sensitivity of PP14 binding
to its receptor. Panel A: 106 PBMC were incubated with *F-PP14
(4 Wg/ml) for 3 h at RT (W W W), 37‡C (- W - W -), or on ice (- - -), com-
pared with unstained cells (999). FACS histograms depict staining
of monocyte-gated PBMC with *F-PP14 at each temperature. Panel
B: 106 PBMC were incubated with *F-PP14 (3 Wg/ml) for 3 h at
RT at pH 9 (W W W), pH 6 (- - -), and pH 7.5 (- W - W -), compared
with unstained cells (999). FACS histograms depict staining of
monocyte-gated PBMC with *F-PP14 at each pH.
Fig. 3. Survey of lipocalin binding to CD14 monocytes. Two-color £ow cytometric analysis was performed as described previously, detecting
CD14 epitopes on the y-axes and £uoresceinated lipocalins on the x-axes. *F-L-lactoglobulin (1.7 Wg/ml; panel C) bound to CD14 cells,
though to a lesser extent than did *F-PP14 (2 Wg/ml; panel A). A 100-fold excess of unlabeled PP14 inhibited binding of both *F-PP14 (panel
B) and *F-L-lactoglobulin (panel D) to CD14 cells. Two other lipocalins, *F-RBP (2.5 Wg/ml panel E) and *F-murine 24p3 (2 Wg/ml; panel
F), failed to bind to CD14 cells.
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binding (Fig. 6A). Scatchard analysis for a representative ex-
periment estimated a KD of 0.67 þ 0.11U1038 (Fig. 6B) with a
range of 0.67^2.8U1038 in four similar experiments. Based on
the assumption (supported by the £ow cytometric data) that
the recombinant PP14 is binding selectively to the CD14
subpopulation within the PBMC, the number of binding sites
per cell ranged from 9510 to 35 820. 125I-PP14 also failed to
bind detectably to both puri¢ed T cells and the Jurkat T cell
line (data not shown). Neither 125I-RBP nor 125I-24p3 bound
signi¢cantly to PBMC (data not shown). Hence, the binding
data with 125I-PP14 and other iodinated lipocalins mirrored
the cell binding selectivity of the £uoresceinated counterparts.
Also of note, 125I-PP14 binding to PBMC was not inhibited
by cold competition with K1-microglobulin, another lipocalin
previously reported to bind to cells of monocytic lineage (data
not shown) [18].
4. Discussion
The lipocalin PP14 is of considerable interest due to its
abundance in amniotic and seminal £uids, presence in preg-
nancy serum and platelets, and intriguing immunomodulatory
properties. In search of a receptor for this protein, we focused
on PBMC, prompted by the immune connection. Recombi-
nant human PP14, produced in a bacterial periplasmic expres-
sion system, was used here for the ¢rst time as a probe to
screen for a PP14 surface receptor. The primary ¢ndings were
as follows. (i) Using two-color £ow cytometry, in conjunction
with £uoresceinated PP14 as a probe, a receptor for PP14 was
readily detected on all CD14 cells, an immunophenotype of
the monocytic lineage; (ii) radiometric data using radio-iodi-
nated PP14 as probe similarly pointed to the monocyte-en-
riched cell population as receptor-bearing cells ; (iii) the radio-
metric analyses further established an approximate KD of
1U1038 for the interaction between recombinant PP14 and
its monocytic receptor; (iv) the receptor for PP14 was
shown to be protease- and pH-sensitive, consistent with its
being a protein; and (v) a receptor for PP14 could not be
detected on other cell types within PBMC when £uorescein-
ated periplasmic PP14 was used as a probe in this experimen-
tal system.
Receptors have been reported previously for several lipoca-
lins, including RBP [12^16], L-lactoglobulin [20], purpurin
[21], odorant binding protein [17], and K1-microglobulin
[18,19]. Interestingly, the receptor for K1-microglobulin was
detected on cells of the monocytic lineage [18]. However,
K1-microglobulin did not e¡ectively compete for binding of
125I-PP14 to monocyte-enriched PBMC, suggesting that these
two lipocalins bind distinct receptors on monocytes. The
present report adds PP14 and L-lactoglobulin to the list of
lipocalins with receptors on monocytic cells. Of note, the pre-
vious report of a L-lactoglobulin receptor localized it to calf
intestine microvilli [20]. Signi¢cantly, PP14 e¡ectively com-
peted with L-lactoglobulin for binding to the monocytic re-
ceptor. However, the precise relationship of the K1-micro-
globulin, PP14, and L-lactoglobulin receptors remains to be
determined.
A number of years ago, Bolton and coworkers reported
that PP14 interferes with interleukin-1 (IL-1) production in
phytohemagglutinin (PHA)-treated PBMC cultures [7]. Since
monocytes are a primary source of IL-1, it is possible that
PP14 negatively signals CD14 monocytes through the recep-
tor identi¢ed in the present study, and thereby reduces IL-1
production by these cells. However, notwithstanding the sim-
plicity of this model, other mechanisms cannot be ruled out at
this stage. For example, the monocytic receptor could serve as
a docking site for PP14, which upon PP14 engagement pro-
motes the release of bioactive ligands (e.g. retinoids) that are
transported within the PP14 hydrophobic pocket. With re-
spect to the latter possibility, it is interesting to note that
PP14 can selectively engage certain retinoids (Mao, J. and
Tykocinski, M., in preparation) and that retinoids have docu-
mented immunosuppressive properties. Hence, ‘docked’ PP14
could serve as a local reservoir of an immunomodulatory
ligand, or even as a reservoir for PP14 itself. This ‘bioactive
PP14 reservoir’ model would parallel that proposed for the
receptor for another immunosuppressive protein, the TGF-L
type III receptor (betaglycan) [29]. Additional experiments
will be required to sort through these functional possibil-
ities.
The present study represents the ¢rst report of a PP14 re-
ceptor and sets the stage for its more detailed characterization
at a molecular level. Insights into PP14’s local and systemic
activities should emerge.
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Fig. 6. Competition and Scatchard plots 125I-PP14 binding to mono-
cyte-enriched PBMC. A: 125I-PP14 (6 ng/ml) was incubated with
cells for 3 h at RT in the presence of increasing amounts of unla-
beled recombinant PP14. After pelleting and washing of the cells,
bound radioactivity within the pellets was determined. Non-speci¢c
binding (binding in the presence of s 50 pmol unlabeled PP14) was
682 cpm. Each point represents the mean of duplicates þ S.E. Data
is representative of results obtained in four similar experiments. B:
The data from the competition curve in A was used to derive a
Scatchard plot.
R.E. Miller et al./FEBS Letters 436 (1998) 455^460 459
Acknowledgements: This work was supported in part by R01 AI38960
from the National Institutes of Health. We thank Dr. M. Lamm and
Dr. S. Shurin for their long-term support, as well as G. Riely, Dr. K.
Rachmilewitz, Dr. N. Xiong, J. Mao and Dr. D. Cibrik for helpful
discussions. We also thank Susi Brill for her expert secretarial assist-
ance in preparation of the manuscript.
References
[1] Julkunen, M., Wahlstrom, T., Seppala, M., Koistinen, R., Kos-
kimies, A., Stenman, U.-H. and Bohn, H. (1984) Arch. Androl.
Suppl. 12, 59^67.
[2] Julkunen, M., Rutanen, E.-M., Koskimies, A., Ranta, T., Bohn,
H. and Seppala, M. (1985) Br. J. Obstet. Gynecol. 92, 1145^1151.
[3] Morrow, D.M., Xiong, N., Getty, R.R., Mariusz, Z.R., Morgan,
D., Seppala, M., Riittinen, L., Gewirtz, A.M. and Tykocinski,
M.L. (1994) Am. J. Pathol. 145, 1485^1495.
[4] Kamarainen, M., Riittinen, L., Seppala, M., Palotie, A. and An-
dersson, L.C. (1994) Blood 84, 467^473.
[5] Dell, A., Morris, H.R., Easton, R.L., Panico, M., Patankar, M.,
Oehninger, S., Koistinen, R., Koistinen, H., Seppala, M. and
Clark, G.F. (1995) J. Biol. Chem. 270, 24116^24126.
[6] Pockley, A.G. and Bolton, A.E. (1989) Clin. Exp. Immunol. 77,
252^256.
[7] Pockley, A.G. and Bolton, A.E. (1990) Immunology 69, 277^281.
[8] Bolton, A.E., Clough, K.G., Stoker, R.J., Pockley, A.G.,
Mowles, E.A., Westwood, O.M.R. and Chapman, M.G. (1987)
Lancet i, 593^595.
[9] Hench, P.S. (1938) Proc. Sta¡ Meetings Mayo Clin. 13, 161^167.
[10] Buyon, J.P. (1998) J. Leukocyte Biol. 63, 281^287.
[11] Flower, D.R. (1996) Biochem. J. 318, 1^14.
[12] Bavik, C.O., Eriksson, U., Allen, R.A. and Peterson, P.A. (1991)
J. Biol. Chem. 266, 14978^14985.
[13] Bavik, C.-O., Busch, C. and Eriksson, U. (1992) J. Biol. Chem.
267, 23035^23042.
[14] Bavik, C.-O., Levy, F., Hellman, U., Wernstedt, C. and Eriksson,
U. (1993) J. Biol. Chem. 268, 20540^20546.
[15] Sivaprasadarao, A. and Findlay, J.B.C. (1988) Biochem. J. 255,
561^569.
[16] Sivaprasadarao, A., Boudjelal, M. and Findlay, J.B.C. (1994)
Biochem. J. 302, 245^251.
[17] Boudjelal, M., Sivaprasadarao, A. and Findlay, J.B.C. (1996)
Biochem. J. 317, 23^27.
[18] Fernandez-Luna, J.L., Leyva-Cobian, F. and Mollinedo, F.
(1988) FEBS Lett. 236, 471^474.
[19] Babiker-Mohamed, H., Akerstrom, B. and Logdberg, L. (1990)
Scand. J. Immunol. 32, 37^44.
[20] Papiz, M.Z., Sawyer, L., Eliopoulos, E.E., North, A.C.T., Find-
lay, J.B.C., Sivaprasadarao, R., Jones, T.A., Newcomer, M.E.
and Kraulis, P.J. (1986) Nature 324, 383^385.
[21] Schubert, D. and LaCorbiere, M. (1985) J. Cell Biol. 100, 56^63.
[22] Gmelig-Meyling, F. and Waldmann, T.A. (1980) J. Immunol.
Methods 33, 1^9.
[23] Yan, M. and Templeton, D.J. (1994) J. Biol. Chem. 269, 19067^
19073.
[24] Tartof, K.D. and Hobbs, C.A. (1987) Bethesda Res. Lab. Focus
9, 12.
[25] Fayen, J., Huang, J.-H., Ferrone, S. and Tykocinski, M.L. (1998)
Int. Immunol., in press.
[26] Flower, D.R., North, A.C.T. and Attwood, T.K. (1991) Bio-
chem. Biophys. Res. Commun. 180, 69^74.
[27] Thorell, J.I. and Johansson, G.B. Biochim. Biophys. Acta 251,
363^369.
[28] Seppala, M., Bohn, H. and Tatarinov, Y. (1998) Tumor Biol. 19,
213^220.
[29] Massague, J., Cheifetz, S., Boyd, F.T. and Andres, J.L. (1990)
Ann. NY Acad. Sci. 593, 59^72.
FEBS 20944 8-10-98
R.E. Miller et al./FEBS Letters 436 (1998) 455^460460
